AXSOME THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
AXSOME THERAPEUTICS, INC. (AXSM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $125.20 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-23
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $128.92, a 52.44% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $84.57, a 29.57% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $65.27, a 117.20% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $30.05, a 54.96% decline year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $125.20, a 48.82% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $84.13, a 24.82% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $67.40, a 74.52% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $38.62, a 27.57% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $125.20 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $123.86 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $124.90 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $128.92 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $84.13 10-K · filed 2025-02-18 | |||
| 2024-09-30 | $83.43 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $83.23 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $84.57 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | $67.40 10-K · filed 2024-02-23 | |||
| 2023-09-30 | $67.87 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $66.28 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $65.27 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $38.62 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $37.03 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $31.62 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $30.05 10-Q · filed 2022-05-02 | |||
| 2021-12-31 | $53.32 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $62.09 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $66.05 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $66.72 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $54.50 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $54.27 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $53.75 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $51.12 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $17.00 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $15.57 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $13.39 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $12.79 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $3.12 10-K · filed 2019-03-15 | |||
| 2018-09-30 | $3.13 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $3.13 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $2.90 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $5.24 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $5.05 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $4.83 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $4.93 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $7.99 10-K · filed 2017-03-07 | |||
| 2016-09-30 | $8.00 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $8.02 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $0.00 10-Q/A · filed 2016-08-09 | |||
| 2015-12-31 | $6.74 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |